Phenotypes associated with this allele

• Allele Symbol: Tg(Igh*-Mir125b-1)116Toki
• Allele Name: transgene insertion 116, Toshio Kitamura
• Allele ID: MGI:5317550
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
tg1	Tg(Igh*-Mir125b-1)116Toki/0	Not Specified	MGI:5317564

Genotype
MGI:5317564

tg1

• Allelic Composition: Tg(Igh*-Mir125b-1)116Toki/0
• Genetic Background: Not Specified

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:178816 )

• all mice develop lethal lymphoid tumors by 35 weeks of age

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:178816 )

• in 1 mouse

immune system

decreased B cell apoptosis ( J:178816 )

• B220+ splenocytes are resistant to serum starvation-induced apoptosis

increased T cell derived lymphoma incidence ( J:178816 )

• in 1 mouse

enlarged spleen ( J:178816 )

increased B cell number ( J:178816 )

• increased B220+/CD19+/IgM-/CD43+ B cells as early as 4 weeks

growth/size/body

enlarged liver ( J:178816 )

enlarged spleen ( J:178816 )

neoplasm

increased lymphoma incidence ( J:178816 )

• all mice develop lethal lymphoid tumors by 35 weeks of age

• tumors cells in the bone marrow and peripheral blood exhibit morphologically lymphoblastic features

increased T cell derived lymphoma incidence ( J:178816 )

• in 1 mouse

increased B cell derived lymphoma incidence ( J:178816 )

• in 10 mice

liver/biliary system

enlarged liver ( J:178816 )

cellular

decreased B cell apoptosis ( J:178816 )

• B220+ splenocytes are resistant to serum starvation-induced apoptosis

hematopoietic system

decreased B cell apoptosis ( J:178816 )

• B220+ splenocytes are resistant to serum starvation-induced apoptosis

increased T cell derived lymphoma incidence ( J:178816 )

• in 1 mouse

enlarged spleen ( J:178816 )

increased bone marrow cell number ( J:178816 )

decreased hemoglobin content ( J:178816 )

increased B cell number ( J:178816 )

• increased B220+/CD19+/IgM-/CD43+ B cells as early as 4 weeks